Prognostic role of serum CA15.3 in 362 node-negative breast cancers. An old player for a new game

被引:53
作者
Gion, M [1 ]
Boracchi, P
Dittadi, R
Biganzoli, E
Peloso, L
Mione, R
Gatti, C
Paccagnella, A
机构
[1] Osped Civile, ULSS12, Ctr Reg Studio Indicatori Biochim Tumore, Venice, Italy
[2] Univ Milan, Ist Stat Med & Biometria, I-20122 Milan, Italy
[3] Ist Nazl Studio & Cura Tumori, Unita Stat & Biometria, I-20133 Milan, Italy
[4] Osped Civile, ULSS12, Div Med Oncol, Venice, Italy
关键词
CA15.3; MUC1; serum markers; breast cancer; node-negative; prognosis; regression splines;
D O I
10.1016/S0959-8049(01)00426-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aims of the present investigation were to evaluate the association between serum CA15.3 levels and other biological and clinical variables and its prognostic rote in patients with node-negative breast cancer. We evaluated 362 patients operated upon primary breast cancer from 1982 to 1992 (median follow-up 69 months). Serum CA15.3 was measured by an immunoradiometric assay. The association between variables was investigated by a Principal Component Analysis (PCA) and the prognostic role of CA15.3 on relapse-free survival (RFS) was investigated by Cox regression models adjusting for age, oestrogen receptor (ER), tumour stage, and ER x age interaction, with both the likelihood ratio test and Harrell's c statistic. The prognostic contribution of CA 15.3 was highly significant. Log relative hazard of relapse was constant until approximately 10 (U/ml) of CA15.3 and increased thereafter with increasing, marker levels. CA15.3 showed a significant contribution using as a cut-off point a value of 31 U/ml. However, the contribution to the model of the marker as a continuous variable is much greater. From these findings, we can conclude that: (i) CA15.3 is a prognostic marker in node-negative breast cancer; (ii) its relationship with prognosis is continuous, with the risk, of relapse increasing progressively from approximately 10 U/ml. (C) Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1181 / 1188
页数:8
相关论文
共 33 条
[1]   Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2 [J].
Agrawal, B ;
Krantz, MJ ;
Reddish, MA ;
Longenecker, BM .
NATURE MEDICINE, 1998, 4 (01) :43-49
[2]   The biological role of mucins in cellular interactions and immune regulation: prospects for cancer immunotherapy [J].
Agrawal, B ;
Gendler, SJ ;
Longenecker, BM .
MOLECULAR MEDICINE TODAY, 1998, 4 (09) :397-403
[3]   DANGERS OF USING OPTIMAL CUTPOINTS IN THE EVALUATION OF PROGNOSTIC FACTORS [J].
ALTMAN, DG ;
LAUSEN, B ;
SAUERBREI, W ;
SCHUMACHER, M .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (11) :829-835
[4]  
ALTMAN DG, 1995, BRIT J CANCER, V72, P518
[5]   Flexible modelling in survival analysis. Structuring biological complexity from the information provided by tumor markers [J].
Biganzoli, E ;
Boracchi, P ;
Daidone, MG ;
Gion, M ;
Marubini, E .
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 1998, 13 (03) :107-123
[6]  
DAVIS BW, 1986, CANCER-AM CANCER SOC, V58, P2662, DOI 10.1002/1097-0142(19861215)58:12<2662::AID-CNCR2820581219>3.0.CO
[7]  
2-Y
[8]   More about: Prognostic importance of low c-erbB2 expression in breast tumors [J].
Dittadi, R ;
Gion, M .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (17) :1443-1443
[9]   Impact of steroid receptors, pS2 and cathepsin D on the outcome of N+ postmenopausal breast cancer patients treated with tamoxifen [J].
Dittadi, R ;
Biganzoli, E ;
Boracchi, P ;
Salbe, C ;
Mione, R ;
Gatti, C ;
Gion, M .
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 1998, 13 (01) :30-41
[10]  
FUNG PYS, 1991, CANCER RES, V51, P1170